共 50 条
Expression of Master Regulators of T-cell, Helper T-cell and Follicular Helper T-cell Differentiation in Angioimmunoblastic T-cell Lymphoma
被引:4
|作者:
Matsumoto, Yosuke
[1
,2
]
Nagoshi, Hisao
[3
]
Yoshida, Mihoko
[1
,2
]
Kato, Seiichi
[4
]
Kuroda, Junya
[3
]
Shimura, Kazuho
[1
,2
]
Kaneko, Hiroto
[1
,2
]
Horiike, Shigeo
[3
]
Nakamura, Shigeo
[4
]
Taniwaki, Masafumi
[1
,2
,5
]
机构:
[1] Aiseikai Yamashina Hosp, Dept Hematol, Kyoto, Japan
[2] Aiseikai Yamashina Hosp, Dept Lab Med, Kyoto, Japan
[3] Kyoto Prefectural Univ Med, Div Hematol, Grad Sch Med Sci, Kyoto, Japan
[4] Nagoya Univ Hosp, Dept Pathol & Lab Med, Nagoya, Aichi, Japan
[5] Kyoto Prefectural Univ Med, Ctr Mol Diagnost & Therapeut, Grad Sch Med Sci, Kyoto, Japan
基金:
日本学术振兴会;
关键词:
angioimmunoblastic T-cell lymphoma;
follicular helper T-cell;
BCL11B;
Th-POK;
BCL6;
TRANSCRIPTION FACTOR;
GENE-EXPRESSION;
BCL11B;
BCL6;
CHECKPOINT;
DIRECTS;
MARKER;
LOCUS;
LEADS;
AITL;
D O I:
10.2169/internalmedicine.8570-16
中图分类号:
R5 [内科学];
学科分类号:
1002 ;
100201 ;
摘要:
Objective It has been postulated that the normal counterpart of angioimmunoblastic T-cell lymphoma (AITL) is the follicular helper T-cell (TFH). Recent immunological studies have identified several transcription factors responsible for T-cell differentiation. The master regulators associated with T-cell, helper T-cell (Th), and TFH differentiation are reportedly BCL11B, Th-POK, and BCL6, respectively. We explored the postulated normal counterpart of AITL with respect to the expression of the master regulators of T-cell differentiation. Methods We performed an immunohistochemical analysis in 15 AITL patients to determine the expression of the master regulators and several surface markers associated with T-cell differentiation. Results BCL11B was detected in 10 patients (67%), and the surface marker of T-cells (CD3) was detected in all patients. Only 2 patients (13%) expressed the marker of naive T-cells (CD45RA), but all patients expressed the marker of effector T-cells (CD45RO). Nine patients expressed Th-POK (60%), and 7 (47%) expressed a set of surface antigens of Th (CD4-positive and CD8-negative). In addition, BCL6 and the surface markers of TFH (CXCL13, PD-1, and SAP) were detected in 11 (73%), 8 (53%), 14 (93%), and all patients, respectively. Th-POK-positive/BCL6-negative patients showed a significantly shorter overall survival (OS) than the other patients (median OS: 33.0 months vs. 74.0 months, p = 0.020; log-rank test). Conclusion Many of the AITL patients analyzed in this study expressed the master regulators of T-cell differentiation. The clarification of the diagnostic significance and pathophysiology based on the expression of these master regulators in AITL is expected in the future.
引用
收藏
页码:2851 / 2856
页数:6
相关论文